Immuneering Corp. () Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

589.6 k

Shareholding (Mar 2025)

FII

6.65%

Held by 35 FIIs

DII

74.58%

Held by 20 DIIs

Promoter

0.00%

How big is Immuneering Corp.?

22-Jun-2025

As of Jun 18, Immuneering Corp. has a market capitalization of 65.49 million and reported net sales of 0.00 million with a net profit of -61.78 million over the latest four quarters. Shareholder's funds are 41.39 million, and total assets are 52.71 million.

What does Immuneering Corp. do?

22-Jun-2025

Immuneering Corp. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $15 million and a market cap of $65.49 million. Key financial metrics include a negative P/E ratio, no dividend yield, and a return on equity of -147.64%.

Is Immuneering Corp. overvalued or undervalued?

25-Jun-2025

As of August 10, 2022, Immuneering Corp. is considered overvalued with significant financial distress, reflected in its negative P/E ratio and other concerning metrics, despite a strong recent stock performance compared to the S&P 500.

Is Immuneering Corp. technically bullish or bearish?

20-Sep-2025

As of August 26, 2025, Immuneering Corp. shows a bullish technical trend with strong moving averages and Bollinger Bands, despite bearish RSI signals, having outperformed the S&P 500 significantly over the past month and year-to-date.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 216 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.90

Return on Equity

-214.71%

Price to Book

7.47

Revenue and Profits:

Net Sales:

(Quarterly Results - Jun 2025)

Net Profit:

-14 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

24.58%

6 Months

241.33%

1 Year

221.63%

2 Years

-19.11%

3 Years

12.82%

4 Years

-65.46%

5 Years

0.0%

Immuneering Corp. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

Is Immuneering Corp. technically bullish or bearish?

As of 26 August 2025, the technical trend for Immuneering Corp. has changed from mildly bullish to bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. Bollinger Bands are bullish for both weekly and monthly periods. Daily moving averages indicate a bullish stance. The KST is bullish on both weekly and monthly time frames. However, the RSI shows a bearish signal for both weekly and monthly periods. Dow Theory indicates no trend on the weekly chart and a mildly bullish trend on the monthly chart. The OBV is also mildly bullish on a monthly basis. In terms of performance, Immuneering Corp. has significantly outperformed the S&P 500 over the past month with a return of 157.43% compared to the S&P 500's 2.33%, and year-to-date, it has returned 309.55% against the S&P 500's 12.22%. Overall, the current technical stance is bullish, driven primarily by the positive signals from moving av...

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-100.00%

EBIT Growth (5y)

-196.91%

EBIT to Interest (avg)

-46.97

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.85

Sales to Capital Employed (avg)

0.00

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

43.13%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.83

EV to EBIT

-0.64

EV to EBITDA

-0.65

EV to Capital Employed

6.50

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

-1014.74%

ROE (Latest)

-147.64%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Mildly Bullish

RSI

No Signal

Bearish

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bullish

Mildly Bearish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 21 Schemes (18.77%)

Foreign Institutions

Held by 35 Foreign Institutions (6.65%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 4.00% vs 17.13% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-14.70",
          "val2": "-15.30",
          "chgp": "3.92%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-14.40",
          "val2": "-15.00",
          "chgp": "4.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs -100.00% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -14.02% vs -5.94% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-63.40",
          "val2": "-57.60",
          "chgp": "-10.07%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-61.00",
          "val2": "-53.50",
          "chgp": "-14.02%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Jun'25

Mar'25

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-14.70

-15.30

3.92%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-14.40

-15.00

4.00%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 4.00% vs 17.13% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-63.40

-57.60

-10.07%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-61.00

-53.50

-14.02%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs -100.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -14.02% vs -5.94% in Dec 2023

All Annual Results

Company CV

About Immuneering Corp.

Immuneering Corp.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available

Immuneering Corp.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Immuneering Corp.?

Watch in Real-Time

What does Immuneering Corp. do?

Is Immuneering Corp. overvalued or undervalued?

Is Immuneering Corp. technically bullish or bearish?

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Is Immuneering Corp. technically bullish or bearish?

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Annual Results Snapshot (Consolidated) - Dec'24

About Immuneering Corp.

Company Coordinates